AMPH

In the past six months (April 2026 - October 2026), Amphastar Pharmaceuticals experienced several stock-impacting events. In February 2026, the FDA approved its Ipratropium Bromide HFA inhalation aerosol, with a Q2 2026 launch planned. In June 2026, the company received FDA approval for an over-the-counter nasal spray for opioid overdose. However, in July 2026, it received an FDA warning letter regarding a facility's manufacturing practices. On August 6, 2026, Amphastar reported Q2 2026 financial results, exceeding expectations with $0.91 EPS (vs. $0.62 consensus) and $183.9 million revenue (vs. $179.92 million estimates). The company presented at the Wells Fargo 21st Annual Healthcare Conference in September 2026. Analyst ratings varied, with Wall Street Zen upgrading it to 'strong-buy' in October 2026, while the broader consensus remained 'Reduce' with a $22.50 price target. Insiders sold $763,922.00 in company stock over the past three months, and short interest decreased by 11.81%, indicating improving investor sentiment.